Venetoclax in Combination with Obinutuzumab in Previously Untreated Fit Patients with Chronic Lymphocytic Leukemia: A Canadian Cost-Utility Analysis
This analysis demonstrates that VEN + O, a 12-month fixed duration treatment, is a cost-effective option for previously untreated fit CLL patients in Canada. VEN + O offers potential health benefits and cost savings when compared with relevant comparator treatments.
Authors
- Lytske Bakker (ORCID: https://orcid.org/0000-0001-8583-0115)
- Shivani Kamdar (ORCID: https://orcid.org/0000-0003-2812-3865)
- Gijs van de Wetering (ORCID: https://orcid.org/0009-0001-6498-2950)
- Versha Banerji (ORCID: https://orcid.org/0000-0002-7415-8818)
- Annie Gosselin
- Nancy Paul Roc
- Carolyn Owen (ORCID: https://orcid.org/0000-0003-4110-1708)
- Beenish S. Manzoor (ORCID: https://orcid.org/0000-0002-0329-3465)
- Gargi Ratnaparkhi
- Stéphane Barakat
- Colin Vicente
Institutions
- University of Calgary (CA)
- AbbVie (United States) (US)
- CancerCare Manitoba (CA)
- ABB (Canada) (CA)
- RED Consulting (Norway) (NO)
- Research Institute in Oncology and Hematology (CA)
- University of Manitoba (CA)
- Open University of the Netherlands (NL)
Publication Details
- Journal
- PharmacoEconomics - Open
- Published
- 2025-11-07
- DOI
- https://doi.org/10.1007/s41669-025-00610-1
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00